Exchange Traded Concepts LLC Has $2.02 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Exchange Traded Concepts LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,250 shares of the biopharmaceutical company’s stock after buying an additional 7,072 shares during the period. Exchange Traded Concepts LLC’s holdings in Pfizer were worth $2,023,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. CX Institutional increased its holdings in shares of Pfizer by 9.1% during the fourth quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 4,183 shares in the last quarter. Sound Income Strategies LLC increased its holdings in shares of Pfizer by 10.0% during the fourth quarter. Sound Income Strategies LLC now owns 764,822 shares of the biopharmaceutical company’s stock worth $20,291,000 after buying an additional 69,416 shares in the last quarter. LexAurum Advisors LLC increased its holdings in shares of Pfizer by 5.0% during the fourth quarter. LexAurum Advisors LLC now owns 28,112 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 1,326 shares in the last quarter. Neumann Capital Management LLC increased its holdings in shares of Pfizer by 50.6% during the fourth quarter. Neumann Capital Management LLC now owns 22,588 shares of the biopharmaceutical company’s stock worth $599,000 after buying an additional 7,587 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its holdings in shares of Pfizer by 7.5% during the fourth quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 2,458,828 shares of the biopharmaceutical company’s stock worth $64,962,000 after buying an additional 172,602 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PFE shares. Guggenheim decreased their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Price Performance

PFE stock opened at $26.10 on Monday. The stock has a market capitalization of $147.89 billion, a PE ratio of 35.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company’s 50-day moving average is $26.11 and its 200-day moving average is $27.94. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. Equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.59%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.